Post BTK inhibitor R/R CLL/SLL BGB-16673 Monotherapy Dose Escalation BGB-16673 Monotherapy Dose Expansion Cohort 2 Post BTK inhibitor ... from EHA® and the author of this poster. Constantine S. Tam,1 Chan Cheah,2,3,4 Don A. Stevens,5 Kunthel By,6 Xiangmei Chen,6 Bilal Tariq,6 Gregory S. Vosganian,6 Jane Huang,6 and Maan Alwan7
• Bruton’s tyrosine kinase (BTK) plays a key role in cell survival in B cell malignancies, and covalent inhibitors of BTK, such as ibrutinib and acalabrutinib, have proven efficacious in chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia1
Protein Degradation Resources - Nurix
Oct 19, 2024 · Access our protein degradation resources below. Access Nurix’s scientific posters, publications, and presentations on protein degradation technology and breakthroughs in cancer and autoimmune research.
• Bruton tyrosine kinase (BTK) plays a critical role in the B-cell antigen receptor signaling pathway and the pathogenesis of multiple B-cell malignancies 1. • Irreversible covalent BTK inhibitors (BTKi) have been instrumental in the management of B-cell malignancies 2, but mutations in BTK can lead to BTKi resistance and limit therapeutic
In this poster, we report safety for all patients and preliminary eficacy in two patients with DLBCL from a phase 1 dose-escalation and cohort-expansion trial evaluating NX-2127 in adults with relapsed/refractory B cell malignancies.
BGB-16673, an investigational drug, is an orally available Bruton’s tyrosine kinase (BTK)-targeted protein degrader and is the first candidate from our Chimeric Degradation Activation Compound (CDAC) platform. THE TARGET: BTK • BTK is a protein that plays an important role in the development and maturation of immune system B-cells.1
Bruton’s tyrosine kinase inhibitors (BTKi) are standard treatment for B-cell malignancies with impressive clinical outcomes. However, diverse BTK mutations emerge during drug treatment which confer resistance to covalent as well as newer version of non-covalent BTKis.
compound with BTK-targeted degradation may bring additional advantage over BTK inhibition for those aggressive diseases. • BGB-16673 is an orally available BTK-targeting chimeric degradation activation (BTK-CDAC) compound designed to …
• Bruton’s tyrosine kinase (BTK) is a key component of the B cell receptor signaling pathway; chronic activation of BTK-mediated B cell receptor signaling is a hallmark of many B cell malignancies. • BTK inhibition has been validated as an effective therapeutic strategy in patients with B cell malignancies; however, emerging patterns of
BTK inhibitors (BTKis) inhibit B cells and prevent innate immune activation via FcR, suggesting that they may be beneficial for treating autoimmune diseases involving B cells.